Accelerate Diagnostics Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics or view top-rated stocks.

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Accelerate Diagnostics saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 10,710,000 shares, a drop of 19.9% from the January 14th total of 13,370,000 shares. Based on an average trading volume of 590,400 shares, the short-interest ratio is currently 18.1 days. Currently, 34.8% of the shares of the stock are short sold.
View Accelerate Diagnostics' Short Interest.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Monday, February, 22nd. The medical research company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.01.
View Accelerate Diagnostics' earnings history.

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXDX shares have decreased by 5.7% and is now trading at $10.01.
View which stocks have been most impacted by COVID-19.

Accelerate Diagnostics issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.1-3.1 million, compared to the consensus revenue estimate of $4.41 million.

3 brokers have issued 12 month price objectives for Accelerate Diagnostics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Accelerate Diagnostics' share price to reach $17.50 in the next twelve months. This suggests a possible upside of 74.8% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Accelerate Diagnostics include Bionano Genomics (BNGO), Fluidigm (FLDM), EyePoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Astrotech (ASTC), Precipio (PRPO), Scientific Industries (SCND), HTG Molecular Diagnostics (HTGM), BioForce Nanosciences (BFNH), Pressure BioSciences (PBIO), Arrayit (ARYC), DiaSys (DYXC), HORIBA (HRIBF), Orthometrix (OMRX) and PositiveID (PSID).
View all of AXDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), MagnaChip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.88%), Credit Suisse AG (2.97%), Chicago Capital LLC (2.82%), Griffin Asset Management Inc. (2.58%), Cannell Peter B & Co. Inc. (1.87%) and Baird Financial Group Inc. (1.64%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, Romney Humphries and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Blair William & Co. IL, Barclays PLC, Trellus Management Company LLC, Bank of New York Mellon Corp, Cutter & CO Brokerage Inc., New York State Common Retirement Fund, and Cannell Peter B & Co. Inc.. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Romney Humphries, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or view top insider-selling stocks.

AXDX stock was bought by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, BlackRock Inc., GSA Capital Partners LLP, Tudor Investment Corp Et Al, Squarepoint Ops LLC, Nuveen Asset Management LLC, and Allworth Financial LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or or view top insider-buying stocks.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXDX stock can currently be purchased for approximately $10.01.

Accelerate Diagnostics has a market capitalization of $595.28 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

Accelerate Diagnostics employs 275 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]